Table 1.

Detectable immune responses in different studies performed in either healthy or oncologic participants after mRNA vaccination.

Participants	Age	Vaccine	Detected Immune Responses	Ref
Healthy	18–55	mRNA-1273	S-specific neutralizing IgGs S-specific Th1 responses	[24]
Healthy	18–55 65–85	BNT162b2	S-specific neutralizing IgGs	[23]
Healthy	12–15	BNT162b2	S-specific neutralizing IgGs	[31]
Healthy	12–17	mRNA-1273	S-specific neutralizing IgGs	[32]
Healthy	18–83	BNT162b2-boost	S-specific neutralizing IgGs S-specific Th1 responses and CD8 T cells	[34]
Healthy	18–55	BNT162b2	S-specific neutralizing IgGs S-specific CD4 and CD8 T cells	[38]
Healthy Naïve and SARS-CoV-2 recovered	22–67	BNT162b2 mRNA-1273	S-specific neutralizing IgGs S-specific CD4 and CD8 T cells Memory B cells	[61]
Solid tumor and oncohematological patients	64–80	BNT162b2	S-specific neutralizing IgGs IFNg-secreting T cells	[63]
Multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) patients	35–81	BNT162b2 mRNA-1273	S-specific serological responses Specific CD8-T-cell responses especially in MM patients	[54]
CLL patients	37–93	BNT162b2 mRNA-1273	Treatment-dependent serological response	[57]
CLL patients	41–88	BNT162b2-boost	Treatment-dependent serological response	[60]
Solid-tumor patients	35–87	BNT162b2	S-specific serological responses	[59]
Solid-tumor patients Naïve and SARS-CoV-2 recovered	40–85	BNT162b2	S-specific IgGs S-specific CD4 and CD8 T cells T-cell phenotypes Myeloid subpopulations	[42]